A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA Public Hospitals Seeking to Avert Penalty Fee Cuts for Low Price Settlements
April 14, 2014
-
BUSINESS 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
-
REGULATORY Chuikyo OKs Listing of 14 APIs including Japan’s First SGLT-2 Inhibitor
April 10, 2014
-
BUSINESS Livalo Lawsuit: Does Use of “PITAVA” by Generic Makers Infringe Kowa Trademark?
April 9, 2014
-
BUSINESS Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
-
BUSINESS India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
April 7, 2014
-
BUSINESS Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
-
BUSINESS Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
-
BUSINESS 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
-
REGULATORY Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
-
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
-
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
-
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
-
ORGANIZATION JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
-
ORGANIZATION Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
-
BUSINESS Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
-
BUSINESS Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
March 26, 2014
-
REGULATORY MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
-
ACADEMIA Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
-
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…